Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
The closing price of Pyxis Oncology Inc (NASDAQ: PYXS) was $1.22 for the day, up 0.83% from the previous closing price of $1.21. In other words, the price has increased by $0.83 from its previous closing price. On the day, 0.56 million shares were traded.
Ratios:
Our analysis of PYXS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 7.75 and its Current Ratio is at 7.75. In the meantime, Its Debt-to-Equity ratio is 0.19 whereas as Long-Term Debt/Eq ratio is at 0.18.
On November 08, 2024, Stephens started tracking the stock assigning a Overweight rating and target price of $13.
On August 08, 2024, Stifel started tracking the stock assigning a Buy rating and target price of $10.Stifel initiated its Buy rating on August 08, 2024, with a $10 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 21 ’25 when HUMPHREY RACHEL bought 13,896 shares for $1.03 per share.
HUMPHREY RACHEL bought 200 shares of PYXS for $194 on Apr 17 ’25. On Apr 14 ’25, another insider, HUMPHREY RACHEL, who serves as the Director of the company, bought 1,400 shares for $0.97 each.
Stock Price History:
Over the past 52 weeks, PYXS has reached a high of $5.39, while it has fallen to a 52-week low of $0.83. The 50-Day Moving Average of the stock is 12.66%, while the 200-Day Moving Average is calculated to be -43.30%.
Shares Statistics:
A total of 61.63M shares are outstanding, with a floating share count of 44.02M. Insiders hold about 28.94% of the company’s shares, while institutions hold 37.56% stake in the company.
